Loperamide, sold under the brand name Imodium, among others,[9] is a medication of the opioid receptor agonist class used to decrease the frequency of diarrhea.[10][11] It is often used for this purpose in irritable bowel syndrome, inflammatory bowel disease, short bowel syndrome,[11] Crohn's disease, and ulcerative colitis.[10] Loperamide is taken by mouth.[11]
Common side effects include abdominal pain, constipation
Loperamide was first made in 1969 and used medically in 1976.[15] It is on the World Health Organization's List of Essential Medicines.[16] Loperamide is available as a generic medication.[11][17] In 2023, it was the 276th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.[18][19]
Loperamide is effective for the treatment of a number of types of diarrhea.[20]
Loperamide is often compared to diphenoxylate. Studies suggest that loperamide is more effective and has lower neural side effects.[21][22][23]
Adverse drug reactions most commonly associated with loperamide are constipation (which occurs in 1.7–5.3% of users), dizziness (up to 1.4%), nausea (0.7–3.2%), and abdominal cramps (0.5–3.0%).[2] Rare, but more serious, side effects include toxic megacolon, paralytic ileus, angioedema, anaphylaxis/allergic reactions, toxic epidermal necrolysis, Stevens–Johnson syndrome, erythema multiforme, urinary retention, and heat stroke.[24] The most frequent symptoms of loperamide overdose are drowsiness, vomiting, and abdominal pain, or burning.[25] High doses may result in heart problems such as abnormal heart rhythms.[26]
Treatment should be avoided in the presence of high fever or if the stool is bloody. Treatment is not recommended for people who could have negative effects from rebound constipation. If suspicion exists of diarrhea associated with organisms that can penetrate the intestinal walls, such as E. coli O157:H7 or Salmonella, loperamide is contraindicated as a primary treatment.[2] Loperamide treatment is not used in symptomatic C. difficile infections, as it increases the risk of toxin retention and precipitation of toxic megacolon.
Loperamide should be administered with caution to people with liver failure due to reduced first-pass metabolism.[27] Additionally, caution should be used when treating people with advanced HIV/AIDS, as cases of both viral and bacterial toxic megacolon have been reported. If abdominal distension is noted, therapy with loperamide should be discontinued.[28]
A review of loperamide in children under twelve years of age found that serious adverse events occurred only in children under three years of age. The study reported that the use of loperamide should be contraindicated in children who are under three years of age, systemically ill, malnourished, moderately dehydrated, or have bloody diarrhea.[29]
In 1990, all formulations of loperamide for children were banned in Pakistan.[30]
Formulations for children aged less than twelve years of age are only available via prescription in the UK.[31]
Loperamide is not recommended in the United Kingdom for use during pregnancy or by nursing mothers.[32] Studies in rat models have shown no teratogenicity, but sufficient studies in humans have not been conducted.[33] One controlled, prospective study of 89 women exposed to loperamide during their first trimester of pregnancy showed no increased risk of malformations. This, however, was only one study with a small sample size.[34] Loperamide can be present in breast milk and is not recommended for breastfeeding mothers.[28]
Loperamide is a substrate of P-glycoprotein; therefore, the concentration of loperamide increases when given with a P-glycoprotein inhibitor.[2] Common P-glycoprotein inhibitors include quinidine, ritonavir, and ketoconazole.[35] Loperamide can decrease the absorption of some other drugs. As an example, saquinavir concentrations can decrease by half when given with loperamide.[2]
Loperamide is an antidiarrheal agent, which decreases intestinal movement. As such, when combined with other antimotility drugs, the risk of constipation is increased. These drugs include other opioids, antihistamines, antipsychotics, and anticholinergics.[36]
Loperamide is an opioid-receptor agonist and acts on the μ-opioid receptors in the myenteric plexus of the large intestine. It works like morphine, decreasing the activity of the myenteric plexus, which decreases the tone of the longitudinal and circular smooth muscles of the intestinal wall.[37][38] This increases the time material stays in the intestine, allowing more water to be absorbed from the fecal matter. It also decreases colonic mass movements and suppresses the gastrocolic reflex.[39]
Loperamide's circulation in the bloodstream is limited in two ways. Efflux by P-glycoprotein in the intestinal wall reduces the passage of loperamide, and the fraction of drug crossing is then further reduced through first-pass metabolism by the liver.[40][41] Loperamide metabolizes into an MPTP-like compound, but is unlikely to exert neurotoxicity.[42]
Efflux by P-glycoprotein also prevents circulating loperamide from effectively crossing the blood-brain barrier,[43] so it can generally only agonize mu-opioid receptors in the peripheral nervous system, and currently has a score of one on the anticholinergic cognitive burden scale.[44] Concurrent administration of P-glycoprotein inhibitors such as quinidine potentially allows loperamide to cross the blood-brain barrier and produce central morphine-like effects. At high doses (>70mg), loperamide can saturate P-glycoprotein (thus overcoming the efflux) and produce euphoric effects.[45] Loperamide taken with quinidine was found to produce respiratory depression, indicative of central opioid action.[46]
High doses of loperamide have been shown to cause a mild physical dependence during preclinical studies, specifically in mice, rats, and rhesus monkeys. Symptoms of mild opiate withdrawal were observed following abrupt discontinuation of long-term treatment of animals with loperamide.[47]
Loperamide is synthesized starting from the lactone 3,3-diphenyldihydrofuran-2(3H)-one and ethyl 4-oxopiperidine-1-carboxylate, on a lab scale.[49] On a large scale a similar synthesis is followed, except that the lactone and piperidinone are produced from cheaper materials rather than purchased.[50][51]
Loperamide is typically manufactured as the hydrochloride salt. Its main polymorph has a melting point of 224 °C and a second polymorph exists with a melting point of 218 °C. A tetrahydrate form has been identified which melts at 190 °C.[52]
Loperamide hydrochloride was first synthesized in 1969[15] by Paul Janssen from Janssen Pharmaceuticals in Beerse, Belgium, following previous discoveries of diphenoxylate hydrochloride (1956) and fentanyl citrate (1960).[53]
The first clinical reports on loperamide were published in 1973[49] with the inventor being one of the authors. The trial name for it was "R-18553".[54] Loperamide oxide has a different research code: R-58425.[55]
The trial against placebo was conducted from December 1972 to February 1974, its results being published in 1977.[56]
In 1973, Janssen started to promote loperamide under the brand name Imodium. In December 1976, Imodium got US FDA approval.[57]
During the 1980s, Imodium became the best-selling prescription antidiarrheal in the United States.[58]
In March 1988, McNeil Pharmaceutical began selling loperamide as an over-the-counter drug under the brand name Imodium A-D.[59]
In the 1980s, loperamide also existed in the form of drops (Imodium Drops) and syrup. Initially, it was intended for children's usage, but Johnson & Johnson voluntarily withdrew it from the market in 1990 after 18 cases of paralytic ileus (resulting in six deaths) were registered in Pakistan and reported by the World Health Organization (WHO).[60] In the following years (1990-1991), products containing loperamide have been restricted for children's use in several countries (ranging from two to five years of age).[61]
In the 1980s, before the US patent expired on 30 January 1990,[58] McNeil started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented this combination.[62] The drug was approved in June 1997, by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet.[63] A caplet formulation was approved in November 2000.[64]
In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology.[65][66]
In 2013, loperamide was added to the WHO Model List of Essential Medicines.[16][67]
Loperamide was formerly a controlled substance in the United States. First, it was a Schedule II controlled substance. However, this was lowered to Schedule V. Loperamide was finally removed from control by the Drug Enforcement Administration in 1982, courtesy of then-Administrator Francis M. Mullen Jr.[68]
Loperamide can be sold freely to the public and is available in most supermarkets, convenience stores and chemists for the treatment of diarrhea and acute diarrhea associated with medically diagnosed irritable bowel syndrome to adults 18 years of age and older.[69]
Loperamide was formerly a controlled substance in the United States. First, it was a Schedule II controlled substance. However, this was lowered to Schedule V. Loperamide was finally removed from control by the Drug Enforcement Administration in 1982, courtesy of then-Administrator Francis M. Mullen Jr.[68]
Loperamide can be sold freely to the public and is available in most supermarkets, convenience stores and chemists for the treatment of diarrhea and acute diarrhea associated with medically diagnosed irritable bowel syndrome to adults 18 years of age and older.[69]
Loperamide is available as a generic medication.[11][17] In 2016, Imodium was one of the biggest-selling branded over-the-counter medications sold in Great Britain, with sales of £32.7 million.[70]
Loperamide was originally sold as Imodium, and many generic brands are sold.[9]
Loperamide has typically been deemed to have a relatively low risk of misuse.[71] In 2012, no reports of loperamide abuse were made.[72] In 2015, however, case reports of extremely high-dose loperamide use were published.[73][74] The primary intent of users has been to manage symptoms of opioid withdrawal such as diarrhea, although a small portion derive psychoactive effects at these higher doses. At these higher doses central nervous system penetration occurs and long-term use may lead to tolerance, dependence, and withdrawal on abrupt cessation.[75] Dubbing it "the poor man's methadone", clinicians warned that increased restrictions on the availability of prescription opioids enacted in response to the opioid epidemic were prompting recreational users to turn to loperamide as an over-the-counter treatment for withdrawal symptoms.[76]
In 2020, some research found that loperamide is effective at killing glioblastoma cells.[82]
